Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded at D. Boral Capital

D. Boral Capital upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a buy rating in a report released on Monday, MarketBeat.com reports. They currently have $9.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Trading Up 2.3 %

Citius Pharmaceuticals stock opened at $4.00 on Monday. The company has a market capitalization of $30.91 million, a PE ratio of -0.67 and a beta of 1.48. The stock has a 50-day moving average price of $5.43 and a two-hundred day moving average price of $11.89. Citius Pharmaceuticals has a 12 month low of $2.44 and a 12 month high of $26.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Chelsea Counsel Co. increased its stake in shares of Citius Pharmaceuticals by 9.8% in the third quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock valued at $141,000 after buying an additional 25,000 shares during the period. Virtu Financial LLC bought a new stake in Citius Pharmaceuticals in the third quarter valued at approximately $50,000. Geode Capital Management LLC increased its position in Citius Pharmaceuticals by 14.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after purchasing an additional 232,656 shares during the period. XTX Topco Ltd bought a new position in Citius Pharmaceuticals during the 3rd quarter worth approximately $47,000. Finally, Miller Investment Management LP lifted its position in shares of Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares during the period. 16.88% of the stock is owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.